Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study-Reference-Cited by-同舟云学术

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

Published:2018-11-08 Issue:5 Volume:183 Page:755-765
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Iannitto Emilio¹^ORCID,Bellei Monica²,Amorim Sandy³,Ferreri Andrés J. M.⁴,Marcheselli Luigi²,Cesaretti Marina²,Haioun Corinne⁵,Mancuso Salvatrice¹,Bouabdallah Krimo⁶,Gressin Remy⁷⁸,Tripodo Claudio⁹,Traverse‐Glehen Alexandra¹⁰,Baseggio Lucile¹¹^ORCID,Zupo Simonetta¹²,Stelitano Caterina¹³,Castagnari Barbara¹⁴,Patti Caterina¹⁵,Alvarez Isabel¹⁶,Liberati Anna Marina¹⁷,Merli Michele¹⁸,Gini Guido¹⁹,Cabras Maria Giuseppina²⁰,Dupuis Jean²¹,Tessoulin Benoit²²,Perrot Aurore²³^ORCID,Re Francesca²⁴,Palombi Francesca²⁵,Gulino Alessandro⁹,Zucca Emanuele²⁶,Federico Massimo²⁷,Thieblemont Catherine²⁸

Affiliation:

1. Department of Oncology ‐ Haematology Unit AOU Policlinico P. Giaccone Palermo Italy

2. Fondazione Italiana Linfomi (FIL) c/o Department of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia Modena Italy

3. APHP, Saint‐Louis Hospital Haemato‐Oncology Paris France

4. Lymphoma Unit IRCCS San Raffaele Scientific Institute Milano Italy

5. Lymphoid Malignancies Unit University Hospital Henri Mondor Creteil France

6. Service d'hématologie CHU Bordeaux Bordeaux France

7. Onco‐Haematology Department University Hospital Grenoble Grenoble France

8. INSERM, U823 Génétique et Epigenetique des cancers lymphoïdes Institut Albert Bonniot Grenoble France

9. Tumour Immunology Unit Human Pathology Section Department of Health Science University of Palermo Palermo Italy

10. Centre Hospitalier Lyon sud service d'anatomie pathologique Université Lyon 1 Pierre Benite France

11. Centre Hospitalier Lyon Sud Laboratoire d'Hématologie cellulaire Université Lyon 1 Pierre Benite France

12. Molecular Diagnostic Unit Policlinico San Martino Genova Italy

13. Division of Haematology Azienda Ospedaliera Bianchi‐Melacrino‐Morelli Reggio Calabria Italy

14. Hospital Santa Maria delle Croci UOC of Haematology Ravenna Italy

15. Division of Haematology Azienda Ospedali Riuniti Villa Sofia‐Cervello Palermo Italy

16. Arcispedale Santa Maria Nuova UOC of Haematology AUSL Reggio Emilia/IRCCS Reggio Emilia Italy

17. Santa Maria Hospital Oncology‐Haematology Perugia University of Perugia Perugia Italy

18. University Hospital Ospedale di Circolo e Fondazione Macchi ASST Settelaghi Varese Italy

19. Division of Haematology Ospedali Riuniti Ancona Italy

20. Division of Haematology Ospedale Businco Cagliari Italy

21. Lymphoid Malignancies Unit Henri Mondor Hospital Creteil France

22. Department of Clinical Haematology Nantes University Hospital Nantes France

23. Haematology Department University Hospital Vandoeuvre Les Nancy France

24. Azienda Ospedaliero‐Universitaria di Parma UO Ematologia e CTMO Parma Italy

25. Haematology and Stem Cell Transplant Regina Elena National Cancer Institute Rome Italy

26. IOSI, Oncology Institute of Southern Switzerland and IOR Institute of Oncology Research Università della Svizzera Italiana (USI) Bellinzona Switzerland

27. Department of Diagnostic, Clinical, and Public Health Medicine University of Modena and Reggio Emilia Modena Italy

28. APHP, Saint‐Louis Hospital Haemato‐oncology‐ Paris Diderot University Paris France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15641

Reference28 articles.

1. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

2. Splenic marginal zone lymphoma: a prognostic model for clinical use

3. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma